REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 09/09/25
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung CancerGlobeNewsWire • 09/09/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
Regeneron Announces Updated Presentation Time for Upcoming Investor ConferenceGlobeNewsWire • 09/04/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/04/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Cantor Global Healthcare Conference 2025 (Transcript)Seeking Alpha • 09/03/25
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia GravisGlobeNewsWire • 08/26/25
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top AnalystsThe Motley Fool • 08/24/25
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffsCNBC • 08/21/25
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period ExtensionGlobeNewsWire • 08/20/25
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected EarningsBenzinga • 08/04/25
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top AnalystsThe Motley Fool • 08/03/25